Liraglutide's efficacy added to high-dose insulin for Type 2 diabetes patients evaluated in Phase 4 trial
Background
Type 2 Diabetes Mellitus (T2DM) often progresses to require high-dose insulin, especially in patients with significant insulin resistance. Despite intensive insulin regimens, achieving optimal glycemic control can be challenging, leading to persistent hyperglycemia and increased risk of complications. Current standard-of-care for severe insulin resistance often involves escalating insulin doses, which can exacerbate weight gain and hypoglycemia. GLP-1 receptor agonists like liraglutide offer a complementary mechanism, enhancing glucose-dependent insulin secretion, suppressing glucagon, and promoting satiety, potentially improving outcomes beyond insulin alone. This study explores if adding liraglutide can break this cycle.
Study Design
This was a Phase 4, randomized, prospective trial (NCT01654120) with 37 enrolled patients diagnosed with Type 2 Diabetes Mellitus and requiring >100 units of insulin daily. Patients were randomized to two arms: an experimental arm receiving Liraglutide 1.8mg SC QD plus titrated insulin for 12 months, and an active comparator arm receiving titrated insulin only for 6 months. The control group then crossed over to receive Liraglutide plus insulin for an additional 6 months. The primary objective was to determine the effect of adding liraglutide to high-dose insulin therapy.
Why It Matters
For patients with severe insulin resistance in Type 2 Diabetes, optimizing glycemic control without excessive insulin burden is a critical challenge. High insulin doses often lead to weight gain and hypoglycemia, limiting treatment efficacy. This study's investigation into combining Liraglutide with high-dose insulin addresses a significant clinical gap. If such combination therapy proves effective (results not provided here), it could offer a pathway to improved glycemic control, reduced insulin requirements, and better patient outcomes. The potential for GLP-1 agonists to enhance insulin sensitivity and mitigate side effects in this population is a key area for advancing T2DM management strategies.